This historical review highlights the evolution of reperfusion therapy for acute myocardial infarction from early pre-clinical studies to a cornerstone of modern cardiology with substantial mortality benefits.
Answers are grounded in this paper and cite their sources.
Reperfusion remains AMI cornerstone; supports megatrial mortality benefit while leaving contemporary refinements open.
Reperfusion therapy for acute myocardial infarction is a milestone achievement in 20th century cardiology. This article tracks this therapy from the discovery that coronary thrombosis is the cause of myocardial infarction, through the pre-clinical era when studies in dogs demonstrated the benefit of early reperfusion. Then came early clinical observations in the feasibility of coronary thrombolysis in patients, followed by the early placebo-controlled megatrials (GISSI-I and ISIS-2), which showed a substantial mortality benefit. During the past decade there have been important refinements using ambulance-based therapy, new bolus thrombolytics, adjunctive glycoprotein inhibitors and percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Eugene Braunwald (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: